This federal Project Grant award of $4,277,148.00 from the Defense Health Agency under the CFDA Program 12.420 - Military Medical Research and Development supports research to identify molecular predictors of risk and objectively validate the evolution of ductal carcinoma in situ (DCIS). The award, effective September 30, 2023, with an ultimate completion date of September 29, 2027, will be performed at Stanford University. Through this grant, Stanford University will conduct basic, translational, and clinical research to develop new treatments, improve patient care, and advance scientific understanding of DCIS. The university will also collaborate with sub-awardees Duke University and Baylor College of Medicine on various aspects of the project, including providing structural oversight, regulatory compliance, operational support, and data analysis. The research aims to transform healthcare for service members and the public through innovative, high-impact biomedical research addressing military health needs.
Mod # | Description | Reason For Modification | Federal Obligation (Click to sort descending) | Date (Click to sort ascending) |
|---|---|---|---|---|
| Not listed | $4.3m | 9/11/23 |
Grant Number | Description | Subgrantee | Prime Award | Dollars Obligated (Click to sort descending) | Updated At (Click to sort ascending) |
|---|---|---|---|---|---|
63346388286813S | Baylor College Of Medicine | Project Grant HT94252311031 | $65.7k | 2/3/25 | |
63346406286813S | Duke University | Project Grant HT94252311031 | $256.7k | 11/18/24 |